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In 2002/03, a novel coronavirus (CoV) termed severe acute
respiratory syndrome (SARS)-CoV emerged in China and
caused an epidemic in which approximately 800 of 8000
cases died. Ten years later, a newly emerged Middle East
respiratory syndrome (MERS)-CoV has been confirmed in
189 patients of which 82 had a fatal outcome. All MERS
cases were linked to the Arabian Peninsula and to date
thirteen cases were imported into the European Union and
Africa. The clinical presentation resembles that of SARS-
CoV as both viruses affect mainly the lower respiratory
tract. As for other mammalian CoV, bats harbor a high
diversity of related viruses and are suspected to be the ani-
mal reservoir. Recent studies have revealed that dromedary
camels are the most likely intermediate host. MERS-CoV
has been circulating in dromedary camels for decades rais-
ing the question whether earlier human cases may have
remained undetected. Preliminary serological surveys in
Saudi Arabia could not determine increased seroprevalence
for MERS-CoV antibodies in the population. The possibi-
lity of human to human transmission has been demon-
strated but is clearly limited. The dipeptidyl peptidase-4
(DPP4) was identified as a cellular receptor for MERS-CoV
entry. DPP4 was found predominantly on non-ciliated
bronchial epithelial and alveolar cells in the lower parts of
the lungs. This might explain the lack of secondary infec-
tions because exposure to high doses of viruses may be
necessary. In-vitro studies showed that MERS-CoV inhib-
ited important cellular pathways in particular the interferon
(IFN) response. Confirmatory in-vivo experiments are still
limited due to the lack of a suitable animal model. Non-
human primates were shown to be susceptible but did not
develop a disease to an extent as humans. A combination
of pegylated IFN-alpha and ribavirin improved the clinical
symptoms confirming previous in-vitro experiments.
The development of vaccines is ongoing and vaccination
programs in dromedary camels might be the optimal
choice to control the current outbreak and prevent future
re-introductions into the human population.
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